세계의 항고지혈증제 시장 : 약제 클래스별 - 기회 분석과 산업 예측(2019-2026년)

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 항고지혈증제 시장은 2018년에 94억 5,600만 달러를 기록했습니다. 시장은 2019-2026년간 7.5%의 CAGR로 성장할 전망이며, 2026년에는 168억 6,400만 달러에 달할 것으로 예측됩니다. 시장 성장 촉진요인으로 좌식 생활방식의 급증, 혈중 콜레스테롤치 분포와 관련된 장애 발생률 상승 등을 들 수 있습니다. 또한 고지혈증과 관련된 합병증에 관한 인식 상승은 시장 성장을 촉진하는 다른 주요 요인입니다. 치료의 높은 비용에 의해 시장 성장이 저해될 수 있지만, 신흥 국가의 경제 성장은 예측기간 중 시장 성장에 유리한 기회를 제공할 것으로 기대되고 있습니다.

세계의 항고지혈증제(Antihyperlipidemic Drugs) 시장에 대해 조사했으며, 시장 기회, 성장 촉진요인 및 저해요인, 약제 클래스·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 서론

• 보고서 설명
• 주요 시장 부문
  • 본 보고서에 게재된 주요 기업 리스트
• 조사 방법
  • 1차 조사
  • 2차 조사
  • 애널리스트의 툴과 모델

제2장 주요 요약

• 주요 조사 결과
• Cxo의 견해

제3장 시장 개요

• 시장 정의와 범위
• 주요 기업의 포지셔닝
  • 주요 투자 재원
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 저해요인
  • 시장 기회
  • 영향 분석

제4장 시장 분석 : 약제 클래스별

• 개요
  • 시장 규모와 예측
• 스타틴
• 담산 봉쇄제
• 콜레스테롤 흡수 억제제
• 피브린산 유도체
• PCSK9 억제제
• 조합
• 기타

제5장 시장 분석 : 지역별

• 개요
  • 시장 규모와 예측
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카, 중동 및 아프리카

제6장 기업 개요

• Abbvie Inc.
• Amgen Inc.
• Astrazeneca Plc
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Dr. Reddy'S Laboratories Ltd
• Merck & Co., Inc
• Mylan N.V
• Pfizer Inc.
• Sanofi S.A.

List of Tables

Table 01. Global Antihyperlipidemic Drugs Market, By Drug Class, 2018-2026 ($Million )

Table 02. Statins Antihyperlipidemic Drugs Market, By Region, 2018-2026 ($Million)

Table 03. Bile Acid Sequestrants Antihyperlipidemic Drugs Market, By Region, 2018-2026 ($Million)

Table 04. Cholesterol Absorption Inhibitors Antihyperlipidemic Drugs Market, By Region, 2018-2026 ($Million)

Table 05. Fibric Acid Derivatives Antihyperlipidemic Drugs Market, By Region, 2018-2026 ($Million)

Table 06. Pcsk9 Inhibitors Antihyperlipidemic Drugs Market, By Region, 2018-2026 ($Million)

Table 07. Combination Antihyperlipidemic Drugs Market, By Region, 2018-2026 ($Million)

Table 08. Others Antihyperlipidemic Drugs Market, By Region, 2018-2026 ($Million)

Table 09. Antihyperlipidemic Drugs Market, By Region, 2018-2026 ($Million )

Table 10. North America Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 ($Million)

Table 11. U.S. Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 12. Canada Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 13. Mexico Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 14. North America Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026($Million)

Table 15. Europe Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 ($Million)

Table 16. Germany Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 17. France Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 18. Uk Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 19. Italy Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 20. Rest of Europe Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 21. Europe Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026($Million)

Table 22. Asia-Pacific Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 ($Million)

Table 23. Japan Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 24. China Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 25. India Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 26. Rest of Asia-Pacific Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 27. Asia-Pacific Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026($Million)

Table 28. Lamea Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 ($Million)

Table 29. Brazil Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 30. South Africa Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 31. Saudi Arabia Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 32. Rest of Lamea Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 ($Million)

Table 33. Lamea Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026($Million)

Table 34. Abbvie: Company Snapshot

Table 35. Abbvie: Operating Business Segments

Table 36. Abbvie: Product Portfolio

Table 37. Amgen: Company Snapshot

Table 38. Amgen: Product Business Segment

Table 39. Amgen: Product Portfolio

Table 40. Astrazeneca: Company Snapshot

Table 41. Astrazeneca: Operating Business Segments

Table 42. Astrazeneca: Product Portfolio

Table 43. Bms: Company Snapshot

Table 44. Bms: Operating Segments

Table 45. Bms: Product Portfolio

Table 46. Daiichi-Sankyo.: Company Snapshot

Table 47. Daiichi-Sankyo.: Operating Business Segments

Table 48. Daiichi-Sankyo.: Product Portfolio

Table 49. Dr.Reddy'S: Company Snapshot

Table 50. Dr. Reddy'S: Operating Business Segments

Table 51. Dr. Reddy'S: Product Portfolio

Table 52. Merck: Company Snapshot

Table 53. Merck: Operating Segments

Table 54. Merck: Product Portfolio

Table 55. Mylan: Company Snapshot

Table 56. Mylan: Operating Segments

Table 57. Mylan: Product Portfolio

Table 58. Pfizer: Company Snapshot

Table 59. Pfizer: Operating Segments

Table 60. Pfizer: Product Portfolio

Table 61. Sanofi: Company Snapshot

Table 62. Sanofi: Product Portfolio

List of Figures

Figure 01. Global Antihyperlipidemic Drugs Market Segmentation

Figure 02. Top Player Positioning, 2018

Figure 03. Top Investment Pockets

Figure 04. Moderate Bargaining Power of Supplier

Figure 05. Low Bargaining Power of Buyers

Figure 06. Low Threat of Substitutes

Figure 07. High Intensity of Rivalry

Figure 08. Low Threat of New Entrant

Figure 09. Impact Analyses, Antihyperlipidemic Drugs Market

Figure 10. Comparative Share Analysis of Statins Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 11. Comparative Share Analysis of Bile Acid Sequestrants Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Cholesterol Absorption Inhibitors Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 13. Comparative Share Analysis of Fibric Acid Derivatives Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 14. Comparative Share Analysis of Pcsk9 Inhibitors Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 15. Comparative Share Analysis of Combination Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 16. Comparative Share Analysis of Others Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 17. U.S. Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 18. Canada Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 19. Mexico Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 20. Germany Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 21. France Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 22. Uk Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 23. Italy Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 24. Rest of Europe Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 25. Japan Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 26. China Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 27. India Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 28. Rest of Asia-Pacific Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 29. Brazil Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 30. South Africa Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 31. Saudi Arabia Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 32. Rest of Lamea Antihyperlipidemic Drugs Market, 2018-2026 ($Million)

Figure 33. Abbvie: Net Sales, 2016-2018 ($Million)

Figure 34. Abbvie: Revenue Share By Region, 2018(%)

Figure 35. Amgen: Net Sales, 2016-2018 ($Million)

Figure 36. Amgen: Revenue Share By Region, 2018(%)

Figure 37. Astrazeneca: Net Sales, 2016-2018 ($Million)

Figure 38. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 39. Bms: Net Sales, 2016-2018 ($Million)

Figure 40. Bms: Revenue Share By Region, 2018(%)

Figure 41. Daiichi-Sankyo: Net Sales, 2016-2018 ($Million)

Figure 42. Daiichi-Sankyo: Revenue Share By Segment, 2018 (%)

Figure 43. Daiichi-Sankyo: Revenue Share By Region, 2018(%)

Figure 44. Dr. Reddy'S: Net Sales, 2016-2018 ($Million)

Figure 45. Dr. Reddy'S: Revenue Share By Segment, 2018 (%)

Figure 46. Dr. Reddy'S: Revenue Share By Region, 2018(%)

Figure 47. Merck: Net Sales, 2016-2018 ($Million)

Figure 48. Merck: Revenue Share By Segment, 2018 (%)

Figure 49. Merck: Revenue Share By Region, 2018(%)

Figure 50. Mylan: Net Sales, 2016-2018 ($Million)

Figure 51. Mylan: Revenue Share By Geography, 2018 (%)

Figure 52. Pfizer: Net Sales, 2016-2018 ($Million)

Figure 53. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 54. Pfizer: Revenue Share By Region, 2018(%)

Figure 55. Sanofi: Net Sales, 2016-2018 ($Million)

Figure 56. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 57. Sanofi: Revenue Share By Region, 2018(%)

The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,864 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.

Lipids are defined as the organic compounds that are fatty acids. These fatty acids are essential and serve as building blocks of the cellular membranes in the living organisms. However, surge in level of lipids in the blood leads to their deposition in the arteries. This deposition of the lipids in the arteries leads to blockage, which in turn increases the risk of heart attacks. Therefore, the condition requires early detection and treatment. The treatment of hyperlipidemia is carried out using antihyperlipidemic drugs. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol absorption inhibitors, and others.

The factors that contribute for the growth of the market include surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the market growth. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities for the market growth during the forecast period.

The antihyperlipidemic drugs market size is studied based on segments, drug class and region, to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the antihyperlipidemic drugs market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

XXXXXKEY BENEFITS FOR STAKEHOLDERSYYYYY

This report entails a detailed quantitative analysis along with the current global antihyperlipidemic market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Drug Class

Statins

PCSK9 Inhibitors

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

Fibric Acid Derivatives

Combination

Symptoms Check

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

List of key players profiled in the report:

• Boehringer Ingelheim GmbH
• Merck KGaA
• Johnson and Johnson
• Bayer AG
• Pfizer, Inc.
• Takeda Pharmaceutical Co., Ltd.
• AstraZeneca plc,
•  

Table of Contents

Chapter 1: Introduction

• 1.1. Report Description
• 1.2. Key Market Segments
  • 1.2.1. List of Key Players Profiled In The Report
• 1.3. Research Methodology
  • 1.3.1. Primary Research
  • 1.3.2. Secondary Research
  • 1.3.3. Analyst Tools And Models

Chapter 2: Executive Summary

• 2.1. Key Findings of The Study
• 2.2. Cxo Perspective

Chapter 3: Market Overview

• 3.1. Market Definition And Scope
• 3.2. Top Player Positioning
  • 3.2.1. Top Investment Pockets
• 3.3. Key Forces Shaping Antihyperlipidemic Industry/Market
• 3.4. Market Dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Presence of Guidelines Recommending The Use of Statins
    • 3.4.1.2. Surge In Healthcare Expenditure Worldwide
    • 3.4.1.3. Rise In Prevalence of Hyperlipidemia Across The Globe
  • 3.4.2. Restraint
    • 3.4.2.1. Upcoming Patent Expirations of Drugs
  • 3.4.3. Opportunity
    • 3.4.3.1. High Growth Potential In Developing Economies
  • 3.4.4. Impact Analyses

Chapter 4: Antihyperlipidemic Drugs Market, By Drug Class

• 4.1. Overview
  • 4.1.1. Market Size And Forecast
• 4.2. Statins
  • 4.2.1. Key Market Trends, Growth Factors, And Opportunities
  • 4.2.2. Market Size And Forecast, By Region
  • 4.2.3. Market Analysis By Country
• 4.3. Bile Acid Sequestrants
  • 4.3.1. Key Market Trends, Growth Factors, And Opportunities
  • 4.3.2. Market Size And Forecast, By Region
  • 4.3.3. Market Analysis By Country
• 4.4. Cholesterol Absorption Inhibitors
  • 4.4.1. Key Market Trends, Growth Factors, And Opportunities
  • 4.4.2. Market Size And Forecast, By Region
  • 4.4.3. Market Analysis By Country
• 4.5. Fibric Acid Derivatives
  • 4.5.1. Key Market Trends, Growth Factors, And Opportunities
  • 4.5.2. Market Size And Forecast, By Region
  • 4.5.3. Market Analysis By Country
• 4.6. Pcsk9 Inhibitors
  • 4.6.1. Key Market Trends, Growth Factors, And Opportunities
  • 4.6.2. Market Size And Forecast, By Region
  • 4.6.3. Market Analysis By Country
• 4.7. Combination
  • 4.7.1. Key Market Trends, Growth Factors, And Opportunities
  • 4.7.2. Market Size And Forecast, By Region
  • 4.7.3. Market Analysis By Country
• 4.8. Others
  • 4.8.1. Key Market Trends, Growth Factors, And Opportunities
  • 4.8.2. Market Size And Forecast, By Region
  • 4.8.3. Market Analysis By Country

Chapter 5: Antihyperlipidemic Drugs Market, By Region

• 5.1. Overview
  • 5.1.1. Market Size And Forecast
• 5.2. North America
  • 5.2.1. Key Market Trends And Opportunities
  • 5.2.2. Market Analysis, By Country
    • 5.2.2.1. U.S.
    • 5.2.2.1.1. U.S. Market Size And Forecast, By Drug Class
    • 5.2.2.2. Canada
    • 5.2.2.2.1. Canada Market Size And Forecast, By Drug Class
    • 5.2.2.3. Mexico
    • 5.2.2.3.1. Mexico Market Size And Forecast, By Drug Class
  • 5.2.3. North America Market Size And Forecast, By Drug Class
• 5.3. Europe
  • 5.3.1. Key Market Trends And Opportunities
  • 5.3.2. Market Analysis, By Country
    • 5.3.2.1. Germany
    • 5.3.2.1.1. Germany Market Size And Forecast, By Drug Class
    • 5.3.2.2. France
    • 5.3.2.2.1. France Market Size And Forecast, By Drug Class
    • 5.3.2.3. Uk
    • 5.3.2.3.1. Uk Market Size And Forecast, By Drug Class
    • 5.3.2.4. Italy
    • 5.3.2.4.1. Italy Market Size And Forecast, By Drug Class
    • 5.3.2.5. Rest of Europe
    • 5.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class
  • 5.3.3. Europe Market Size And Forecast, By Drug Class
• 5.4. Asia-Pacific
  • 5.4.1. Key Market Trends And Opportunities
  • 5.4.2. Market Analysis, By Country
    • 5.4.2.1. Japan
    • 5.4.2.1.1. Japan Market Size And Forecast, By Drug Class
    • 5.4.2.2. China
    • 5.4.2.2.1. China Market Size And Forecast, By Drug Class
    • 5.4.2.3. India
    • 5.4.2.3.1. India Market Size And Forecast, By Drug Class
    • 5.4.2.4. Rest of Asia-Pacific
    • 5.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class
  • 5.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
• 5.5. Lamea
  • 5.5.1. Key Market Trends And Opportunities
  • 5.5.2. Market Analysis, By Country
    • 5.5.2.1. Brazil
    • 5.5.2.1.1. Brazil Market Size And Forecast, By Drug Class
    • 5.5.2.2. South Africa
    • 5.5.2.2.1. South Africa Market Size And Forecast, By Drug Class
    • 5.5.2.3. Saudi Arabia
    • 5.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class
    • 5.5.2.4. Rest of Lamea
    • 5.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class
  • 5.5.3. Lamea Market Size And Forecast, By Drug Class

Chapter 6: Company Profiles

• 6.1. Abbvie Inc.
  • 6.1.1. Company Overview
  • 6.1.2. Company Snapshot
  • 6.1.3. Operating Business Segments
  • 6.1.4. Product Portfolio
  • 6.1.5. Business Performance
• 6.2. Amgen Inc.
  • 6.2.1. Company Overview
  • 6.2.2. Company Snapshot
  • 6.2.3. Operating Business Segments
  • 6.2.4. Product Portfolio
  • 6.2.5. Business Performance
  • 6.2.6. Key Strategic Moves And Developments
• 6.3. Astrazeneca Plc
  • 6.3.1. Company Overview
  • 6.3.2. Company Snapshot
  • 6.3.3. Operating Business Segments
  • 6.3.4. Product Portfolio
  • 6.3.5. Business Performance
• 6.4. Bristol-Myers Squibb Company
  • 6.4.1. Company Overview
  • 6.4.2. Company Snapshot
  • 6.4.3. Operating Business Segments
  • 6.4.4. Product Portfolio
  • 6.4.5. Business Performance
• 6.5. Daiichi Sankyo Company, Limited
  • 6.5.1. Company Overview
  • 6.5.2. Operating Business Segments
  • 6.5.3. Product Portfolio
  • 6.5.4. Business Performance
• 6.6. Dr. Reddy'S Laboratories Ltd
  • 6.6.1. Company Overview
  • 6.6.2. Company Snapshot
  • 6.6.3. Operating Business Segments
  • 6.6.4. Product Portfolio
  • 6.6.5. Business Performance
• 6.7. Merck & Co., Inc
  • 6.7.1. Company Overview
  • 6.7.2. Company Snapshot
  • 6.7.3. Operating Business Segments
  • 6.7.4. Product Portfolio
  • 6.7.5. Business Performance
• 6.8. Mylan N.V
  • 6.8.1. Company Overview
  • 6.8.2. Company Snapshot
  • 6.8.3. Operating Business Segments
  • 6.8.4. Product Portfolio
  • 6.8.5. Business Performance
• 6.9. Pfizer Inc.
  • 6.9.1. Company Overview
  • 6.9.2. Company Snapshot
  • 6.9.3. Operating Business Segments
  • 6.9.4. Product Portfolio
  • 6.9.5. Business Performance
• 6.10. Sanofi S.A.
  • 6.10.1. Company Overview
  • 6.10.2. Operating Business Segments
  • 6.10.3. Product Portfolio
  • 6.10.4. Business Performance
  • 6.10.5. Key Strategic Moves And Developments